We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




European Network for Muscle Pathology

By Biotechdaily staff writers
Posted on 21 Mar 2005
A European network called Myores brings together 37 research groups in seven countries who will work toward the understanding of muscle development, function, and repair in order to develop therapies for various muscle pathologies.

Myores will bring together resources to tackle problems in a field that causes considerable suffering. More...
In Europe, more than 300,000 people are affected by various muscular dystrophies, while muscular degeneration is one of the most incapacitating features of aging. Network resources will pool European expertise and share nine high-technology platforms. The network will receive around U.S.$16 million in funding as part of the European Commission's 6th Framework Program for Research and Technical Development.

Three platforms will focus on gene attenuation using interfering RNA (iRNA), Drosophila transgenesis, and in vivo electroporation. Other platforms will focus on proteomics and micro-chips, molecular modeling, and molecular imaging. Data resulting from work on these platforms will be assembled in a common database, Myobase, to facilitate and accelerate access to results for all the network members. The results will help scientists to gain a better understanding of the molecular mechanisms involved in human repairing systems.

The French National Institute for Health and Medical Research (Inserm, Paris, France) will be in charge of the scientific coordination of Myores. Network partners include the University of Sheffield (UK), Clinical University, Freiburg (Germany), Institute Pasteur (France), School of Medicine, Pauda (Italy), Max Planck Institute (Germany), Hebrew University (Israel), Imperial College (London), and many others.





Related Links:
Inserm

New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Pipette Calibration System
Artel PCS®
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.